Takeda Pharmaceutical Company Limited (TAK)
NYSE: TAK · Real-Time Price · USD
15.91
+0.04 (0.25%)
Jun 12, 2026, 4:00 PM EDT - Market closed
Takeda Pharmaceutical Revenue
In the fiscal year ending March 31, 2026, Takeda Pharmaceutical had annual revenue of 4.51T JPY, down -1.66%. Takeda Pharmaceutical had revenue of 1.09T in the quarter ending March 31, 2026, with 3.90% growth.
Revenue (ttm)
4.51T JPY
Revenue Growth
-1.66%
P/S Ratio
1.77
Revenue / Employee
94,947,213 JPY
Employees
47,455
Market Cap
50.12B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.51T | -75.83B | -1.66% |
| Mar 31, 2025 | 4.58T | 317.79B | 7.45% |
| Mar 31, 2024 | 4.26T | 236.28B | 5.87% |
| Mar 31, 2023 | 4.03T | 458.47B | 12.85% |
| Mar 31, 2022 | 3.57T | 371.20B | 11.61% |
| Mar 31, 2021 | 3.20T | -93.38B | -2.84% |
| Mar 31, 2020 | 3.29T | 1.19T | 56.93% |
| Mar 31, 2019 | 2.10T | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.35B |
| Haleon | 14.85B |
| Viatris | 14.56B |
| Zoetis | 9.53B |
| Elanco Animal Health | 4.89B |
| Dr. Reddy's Laboratories | 3.58B |
| United Therapeutics | 3.17B |
| Neurocrine Biosciences | 3.10B |
TAK News
- 3 days ago - Takeda announces results for Phase 3 study of TAK-279 - TheFly
- 3 days ago - Takeda's AI-crafted psoriasis pill tops Bristol Myers' Sotyktu in head-to-head trial - Reuters
- 3 days ago - Takeda's Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations - Business Wire
- 4 days ago - FDA Accepts Takeda's SBLA For ENTYVIO IV In Pediatric UC And Crohn's Disease; PDUFA Set In Q1,2027 - Nasdaq
- 5 days ago - FDA accepts Takeda’s application for intravenous Entyvio - TheFly
- 5 days ago - U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease - Business Wire
- 11 days ago - Takeda Pharmaceutical Company Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 13 days ago - Takeda Pharmaceutical Co Ltd (TAK) Shares Fall 4.8% -- GF Value Says Still Overvalued - GuruFocus